Brain scans may unlock secrets of ALS

NCT ID NCT02567136

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study uses powerful MRI scans to find biomarkers—measurable signs of disease—for amyotrophic lateral sclerosis (ALS) and primary lateral sclerosis (PLS). Researchers will compare brain images from patients and healthy volunteers to better understand these diseases and potentially improve future treatments. The study is currently recruiting 30 participants aged 21 to 75.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
If successful, this study could identify reliable biomarkers for ALS and PLS, leading to earlier diagnosis and better treatment monitoring.
What could go wrong
This is a small, early-stage observational study (30 participants) focused on imaging, not a treatment trial. It may not find clear biomarkers or directly benefit participants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Minnesota

    RECRUITING

    Minneapolis, Minnesota, 55414, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.